ISSN:
1432-1041
Keywords:
Primary hypercholesterolemia
;
treatment of hypercholesterolemia
;
HMG-CoA reductase inhibitor
;
pravastatin
;
lovastatin
;
simvastatin
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Summary The HMG-CoA reductase inhibitors have been shown to cause marked reduction of cholesterol and offer a new and effective approach to treatment of hyperlipoproteinemia. Three agents, pravastatin (P), lovastatin (L) and simvastatin (S), have been studied with reference to long-term lipid-lowering effect, tolerance and clinical safety. Following a dietary lead-in period of at least 6 weeks in every case, patients with primary hypercholesterolemia were enrolled from participants of short-term controlled studies which after completion were extended as open studies. Treatment was administered over 6 months with 20 mg S (84 patients), L (42 patients) or P (23 patients) twice daily. Total cholesterol was decreased with S by 30.2% of basal, with L by 25.5%, and with P by 28.2%. The decrease in apolipoprotein B was 28.4%, of basal, with S 16.4% and in P 19.2%. Triglycerides were lowered by 19.6% of basal with S by 17.4%, with L, and by 6.4% with HDL-cholesterol increased in the S group by 23% of basal, by 9.7% in the L group, and by 8.0% in the P group. No serious clinical or laboratory abnormalities were observed. In the S group headache (3.6% of patients), abdominal discomfort (2.4%), sleeping disturbances (3.6%), and muscle pain (2.4%) were reported. In the L group headache (7.1%), abdominal discomfort (4.8%), sleep disorders (4.8%), and muscle pain (4.8%) were observed. In the P group one patient complained of abdominal discomfort (8.7%) and one of sleep disorders (8.7%). Increases in CPK were observed in the S group (4.8% of patients) and in the L group (11.9%). Increases in SGPT was measured in the S group (3.6% of patients), in the L group (7.1 %) and in the P group (4.4% ). None of the patients had to stop therapy because of adverse events. Clinical experience suggest that simvastatin is the inhibitor with the highest efficacy regarding cholesterol lowering, whereas pravastatin seems to the inhibitor that is best tolerated. However, more data are required for comparison of the complete profiles of these three compounds.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF01409404
Permalink
